Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
This study, called CH CARE, aims to understand how a condition called clonal hematopoiesis (CH) affects people receiving chemotherapy or radiation for solid cancers like breast or lung cancer. CH is a change in blood stem cells. Researchers will collect tissue samples, such as blood, urine, or biopsy tissue, during your regular visits. They will look at these samples to find out how common CH is and how it changes over time, up to five years. This information will help identify cancer patients who might be at higher risk for certain blood disorders after cancer treatment. You can join if you are over 18, have a solid cancer, and are planning to receive chemotherapy or radiation.
- Study design
- This is an observational study, meaning researchers will collect information and samples without giving new treatments. About 5,000 people are expected to participate.
- What's involved
- You would provide tissue samples (like blood, saliva, urine, or biopsy tissue) during routine visits. These samples will be collected at the start, at 6 months, and annually for up to 5 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 5 years, with assessments at the start, 6 months, and annually.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Lachelle D Weeks, MD, PhD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Prevalence of clonal hematopoiesisBaseline
Prevalence of clonal hematopoiesis detected by the study's targeted unique molecular identifier-based sequencing panel in population of adults with advanced non-metastatic solid cancers.
- Gene distribution of clonal hematopoiesisbaseline
Distribution of genes mutated among subpopulation with clonal hematopoiesis in population of adults receiving chemotherapy and radiation therapy for solid malignancy.
- Change in clonal hematopoiesis variant allele fractionUp to 5 years; assessed at time 0, 6 months, and annually
Change in clonal hematopoiesis allelic fractions over follow-up in patients receiving chemotherapy and radiation for advanced non-metastatic solid malignancy, based on serial sequencing of stored blood specimens.
- Solid malignancy progressionUp to 5 years
Solid malignancy progression in relation to the presence of clonal hematopoiesis, based on clinical progression data abstracted from the electronic health record and follow-up data collected under protocol 22-200.
- Overall survivalUp to 5 years
Overall survival in relation to the presence of clonal hematopoiesis, based on abstracted date of death and cause of death.
- Development of hematologic toxicityUp to 5 years
Development of hematologic toxicity in relation to the presence of clonal hematopoiesis, using abstracted clinical and laboratory data, including CBC values and related treatment information.
- Development of therapy-related myeloid neoplasm (t-MN)Up to 10 years
Development of therapy-related myeloid neoplasm in relation to the presence of clonal hematopoiesis, using abstracted dates of diagnosis of hematologic malignancies and related follow-up data.